The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Flagged first, then by citations
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 701–800 of 1,036
Cardiovascular Risk Assessment in Hypertensive Patients
Wang, M. C., & Lloyd‐Jones, D. M. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab021 · Cited by 69
Tomson, C., Cheung, A. K., Mann, J. F. E., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Knoll, G. A., Muntner, P., Pecoits‐Filho, R., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0834 · Cited by 69
Oikonomou, E. K., Spatz, E. S., Suchard, M. A., & Khera, R. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00170-4 · Cited by 69
The Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study
Parksook, W. W., Brown, J. M., Omata, K., Tezuka, Y., Ono, Y., Satoh, F., Tsai, L. C., Niebuhr, Y., Milks, J., Moore, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae145 · Cited by 69
Management of Essential Hypertension
Ferdinand, K. C., & Nasser, S. A. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2016.12.005 · Cited by 69
Heart Failure with Preserved Ejection Fraction in Older Adults
Upadhya, B., & Kitzman, D. W. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.02.005 · Cited by 69
Venkatesan, S., Myles, P. R., Manning, H. J., Mozid, A. M., Andersson, C., Jørgensen, M. E., Hardman, J. G., Moonesinghe, R., Foëx, P., Mythen, M. G., et al. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex056 · Cited by 69
Stop vasodepressor drugs in reflex syncope: a randomised controlled trial
Solari, D., Tesi, F., Unterhuber, M., Gaggioli, G., Ungar, A., Tomaino, M., & Brignole, M. (2017) · Heart · doi:10.1136/heartjnl-2016-309865 · Cited by 68
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Cortesi, P. A., Fornari, C., Madotto, F., Conti, S., Naghavi, M., Bikbov, B. T., Briant, P. S., Caso, V., Crotti, G., Johnson, C. O., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320949414 · Cited by 68
Berry, J. D., Nambi, V., Ambrosius, W. T., Chen, H., Killeen, A. A., Taylor, A. A., Toto, R. D., Soliman, E. Z., McEvoy, J. W., Pandey, A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3187 · Cited by 68
Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
Stewart, J., Addy, K., Campbell, S., & Wilkinson, P. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020949326 · Cited by 68
Cost-effectiveness of Intensive Blood Pressure Management
Richman, I. B., Fairley, M., Jørgensen, M. E., Schuler, A., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3517 · Cited by 68
Luymes, C. H., Poortvliet, R. K. E., van Geloven, N., de Waal, M. W. M., Drewes, Y. M., Blom, J. W., Smidt, N., Assendelft, W. J., van den Hout, W. B., de Ruijter, W., et al. (2018) · BMC Medicine · doi:10.1186/s12916-017-0988-0 · Cited by 68
Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease
Khan, N. A., Rabkin, S. W., Zhao, Y., McAlister, F. A., Park, J. E., Guan, M., Chan, S., & Humphries, K. H. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10177 · Cited by 68
Bos, I., Vos, S. J. B., Schindler, S. E., Hassenstab, J. J., Xiong, C., Grant, E., Verhey, F. R. J., Morris, J. C., Visser, P. J., & Fagan, A. M. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.04.015 · Cited by 68
Summers, N. A., Lahiri, C. D., Angert, C. D., Aldredge, A., Mehta, C. C., Ofotokun, I., Kerchberger, A. M., Gustafson, D., Weiser, S. D., Kassaye, S., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002447 · Cited by 67
Association of Blood Pressure With the Progression of CKD: Findings From KNOW-CKD Study
Lee, J. Y., Park, J. T., Joo, Y. S., Lee, C., Yun, H., Yoo, T., Kang, S., Choi, K. H., Ahn, C., Oh, K., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.12.013 · Cited by 67
Advances in Non-Invasive Blood Pressure Monitoring
Quan, X., Liu, J., Roxlo, T., Siddharth, S., Leong, W., Muir, A., Cheong, S., & Rao, A. V. (2021) · Sensors · doi:10.3390/s21134273 · Cited by 67
Update on Management of Cardiovascular Diseases in Women
Lucà, F., Abrignani, M. G., Parrini, I., Fusco, S. A. D., Giubilato, S., Rao, C. M., Piccioni, L., Cipolletta, L., Passaretti, B., Giallauria, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051176 · Cited by 67
Prospects for the Primary Prevention of Myocardial Infarction and Stroke
Caldwell, M., Martinez, L. C., Foster, J. G., Sherling, D. H., & Hennekens, C. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418817344 · Cited by 67
Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients
Aggarwal, R., Petrie, B., Bala, W., & Chiu, N. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12697 · Cited by 67
How I monitor long-term and late effects after blood or marrow transplantation
Bhatia, S., Armenian, S. H., & Landier, W. (2017) · Blood · doi:10.1182/blood-2017-03-725671 · Cited by 66
Kario, K. (2018) · Circulation · doi:10.1161/circulationaha.117.032851 · Cited by 66
Subclinical Hearing Loss is Associated With Depressive Symptoms
Golub, J. S., Brewster, K., Brickman, A. M., Ciarleglio, A., Kim, A. H., Luchsinger, J. A., & Rutherford, B. R. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.12.008 · Cited by 66
Chen, T., Shao, F., Chen, K., Wang, Y., Wu, Z., Wang, Y., Gao, Y., Cornelius, V. R., Li, C., & Jiang, Z. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.1657 · Cited by 66
Cardiovascular Statistics in the United States, 2026
Wadhera, R. K., Dhruva, S. S., Bikdeli, B., Bonaca, M. P., Kittleson, M. M., Ko, D. T., Lu, Y., Pagidipati, N. J., Sawano, M., Spatz, E. S., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.027 · Cited by 66
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Sitbon, O., & Gaine, S. (2016) · European Respiratory Review · doi:10.1183/16000617.0085-2016 · Cited by 66
Raizada, M. K., Joe, B., Bryan, N. S., Chang, E. B., Dewhirst, F. E., Borisy, G. G., Galis, Z. S., Henderson, W. A., José, P. A., Ketchum, C. J., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09699 · Cited by 66
Filardi, P. P., Coca, A., Galderisi, M., Paolillo, S., Alpendurada, F., SIMONE, G. D., Donal, E., Kahan, T., Mancia, G., Redón, J., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001396 · Cited by 66
Lamprea-Montealegre, J. A., Zelnick, L. R., Hall, Y. N., Bansal, N., & de Boer, I. H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11609 · Cited by 66
Cheng, H., Lin, H., Wang, T., & Chen, C. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13747 · Cited by 66
Boo, S., Yoon, Y. J., & Oh, H. (2018) · Medicine · doi:10.1097/md.0000000000013713 · Cited by 65
Kremer, K.-M., Braisch, U., Rothenbacher, D., Denkinger, M., Dallmeier, D., & for the ActiFE Study Group (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17530 · Cited by 65
Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events
Buckley, L. F., Baker, W. L., Tassell, B. W. V., Cohen, J. B., Alkhezi, O. S., Bress, A. P., & Dixon, D. L. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.20141 · Cited by 65
Wang, Z., Du, X., Hua, C., Li, W., Zhang, H., Liu, X., Wang, Y., Jiang, C., Guo, J., Lv, Q., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064003 · Cited by 65
Clinical practice guideline for the management of hypertension in China
Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange Association, & Cardiovascular Disease Prevention and Rehabilitation Committee, C. A. O. R. M. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003431 · Cited by 66
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
Desai, A. S., Karns, A. D., Badarienė, J., Aswad, A., Neutel, J. M., Kazi, F., Park, W., Stiglitz, D., Makarova, N., Havasi, A., et al. (2025) · JAMA · doi:10.1001/jama.2025.6681 · Cited by 65
Obi, Y., Kalantar‐Zadeh, K., Shintani, A., Kovesdy, C. P., & Hamano, T. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12701 · Cited by 65
Gijón‐Conde, T., Gorostidi, M., Camafort, M., Abad-Cardiel, M., Martín-Rioboó, E., Morales‐Olivas, F. J., Vinyoles, E., Armario, P., Banegas, J. R., Coca, A., et al. (2018) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2018.04.001 · Cited by 65
Muntner, P., Whelton, P. K., Woodward, M., & Carey, R. M. (2018) · Diabetes Care · doi:10.2337/dc18-1307 · Cited by 65
Bullen, A. L., Katz, R., Lee, A. K., Anderson, C. A. M., Cheung, A. K., Garimella, P. S., Jotwani, V., Haley, W. E., Ishani, A., Lash, J. P., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.03.024 · Cited by 65
Kjeldsen, S. E., Narkiewicz, K., Burnier, M., & Oparil, S. (2018) · Blood Pressure · doi:10.1080/08037051.2018.1507621 · Cited by 65
Office Blood Pressure Measurement: The Weak Cornerstone of Hypertension Diagnosis
Stergiou, G., Kollias, A., Parati, G., & O’Brien, E. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.10850 · Cited by 64
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 64
Modern Management and Diagnosis of Hypertension in the United Kingdom: Home Care and Self-care
Sheppard, J. P., Schwartz, C., Tucker, K. L., & McManus, R. J. (2016) · Annals of Global Health · doi:10.1016/j.aogh.2016.02.005 · Cited by 64
Collard, D., Brouwer, T. F., Engberink, R. O., Zwinderman, A. H., Vogt, L., & van den Born, B. H. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14659 · Cited by 64
Generalizability of Blood Pressure Lowering Trials to Older Patients: Cross‐Sectional Analysis
Sheppard, J. P., Lown, M. T., Burt, J., Temple, E., Lowe, R., Ashby, H., Todd, O. M., Allen, J., Ford, G. A., Fraser, R., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16749 · Cited by 64
Blood Pressure and Vascular Cognitive Impairment
Levine, D. A., Springer, M. V., & Brodtmann, A. G. (2022) · Stroke · doi:10.1161/strokeaha.121.036140 · Cited by 63
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
Saiz, L. C., Gorricho, J., Garjón, J., Celaya, M. C., Erviti, J., & Leache, L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010315.pub5 · Cited by 63
Averkov, O. V., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Nikulina, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Abugov, S. A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6319 · Cited by 63
White, W. B., Kupfer, S., Zannad, F. M., Mehta, C. R., Wilson, C., Lei, L., Bakris, G. L., Nissen, S. E., Cushman, W. C., Heller, S. R., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0303 · Cited by 64
Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk
Bergmark, B. A., Scirica, B. M., Steg, P. G., Fanola, C. L., Gurmu, Y., Mosenzon, O., Cahn, A., Raz, I., Bhatt, D. L., & SAVOR-TIMI 53 Investigators (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx809 · Cited by 63
Initial Treatment of Hypertension
Taler, S. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1613481 · Cited by 63
Bress, A. P., Colantonio, L. D., Cooper, R., Kramer, H., Booth, J. N., Odden, M. C., Bibbins-Domingo, K. B., Shimbo, D., Whelton, P. K., Levitan, E. B., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035640 · Cited by 63
Ерина, А. М., Rotar, O. P., Солнцев, В. Н., Shalnova, S. A., Деев, А. Д., Баранова, Е. И., Конради, А. О., Boytsov, S. A., & Shlyakhto, E. V. (2019) · Kardiologiia · doi:10.18087/cardio.2019.6.2595 · Cited by 63
Performance of soluble Klotho assays in clinical samples of kidney disease
Neyra, J. A., Moe, O. W., Pastor, J. V., Gianella, F. G., Sidhu, S. S., Sarnak, M. J., Ix, J. H., & Drew, D. A. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz085 · Cited by 63
Coley, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Andreadis, E. A., Geladari, C. V., Angelopoulos, E. T., Savva, F., Georgantoni, A. I., & Papademetriou, V. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008994 · Cited by 62
Lee, J. H., Kim, S., Kang, S., Cho, J. H., Cho, Y., Oh, I., Yoon, C., Lee, H., Youn, T., Chae, I., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31549-5 · Cited by 62
Medication adherence and treatment-resistant hypertension: a review
Hameed, M. A., & Dasgupta, I. (2019) · Drugs in Context · doi:10.7573/dic.212560 · Cited by 62
Crutzen, S., Baas, G., Abou, J., van den Born-Bondt, T., Hugtenburg, J. G., Bouvy, M. L., Heringa, M., Taxis, K., & Denig, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01268 · Cited by 62
A generalized theory of separable effects in competing event settings
Stensrud, M. J., Hernán, M. Á., Tchetgen, E. J. T., Robins, J. M., Didelez, V., & Young, J. G. (2021) · Lifetime Data Analysis · doi:10.1007/s10985-021-09530-8 · Cited by 62
Lee, H., Kwon, S. H., Jeon, J. S., Noh, H., Han, D. C., & Kim, H. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.099 · Cited by 62
Trends in acute myocardial infarction mortality in the European Union, 2012–2020
Zuin, M., Rigatelli, G., Temporelli, P. L., Fusco, S. A. D., Colivicchi, F., Pasquetto, G., & Bilato, C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad214 · Cited by 62
Tobe, S. W., Stone, J. A., Anderson, T. J., Bacon, S., CHENG, A. Y. Y., Daskalopoulou, S. S., Ezekowitz, J. A., Grégoire, J. C., Gubitz, G. J., Jain, R., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180194 · Cited by 62
Blood Pressure Goals in Patients with CKD
Chang, A. R., Lóser, M. K., Malhotra, R., & Appel, L. J. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07440618 · Cited by 62
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 61
Sex, Oxidative Stress, and Hypertension: Insights From Animal Models
Reckelhoff, J. F., Romero, D. G., & Cardozo, L. L. Y. (2019) · Physiology · doi:10.1152/physiol.00035.2018 · Cited by 61
Nascimento, B. R., Brant, L. C. C., Yadgir, S., de Oliveira, G. M. M., Roth, G. A., Glenn, S., Mooney, M., Naghavi, M., Passos, V. M. D. A., Duncan, B. B., et al. (2020) · Population Health Metrics · doi:10.1186/s12963-020-00218-z · Cited by 61
Pathophysiology and genetics of salt-sensitive hypertension
Maaliki, D. S., Itani, M. M., & Itani, H. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1001434 · Cited by 61
Screening for Kidney Disease in Low- and Middle-Income Countries
Kalyesubula, R., Conroy, A. L., Cálice-Silva, V., Kumar, V., Onu, U. C., Batte, A., Kaze, F. F., Fabian, J., & Ulasi, I. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151315 · Cited by 61
Alcocer, L. A., Bryce, A., Brasil, D., Lara-Terán, J. J., Cortes, J. M., Quesada, D., & Rodriguez, P. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00605-5 · Cited by 63
Patient Perceptions About Prediabetes and Preferences for Diabetes Prevention
O’Brien, M. J., Moran, M. R., Tang, J. W., Vargas, M. C., Talen, M. R., Zimmermann, L. J., Ackermann, R. T., & Kandula, N. R. (2016) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721716666678 · Cited by 61
Steenland, K., Pillarisetti, A., Kirby, M. A., Peel, J. L., Clark, M. L., Checkley, W., Chang, H. H., & Clasen, T. (2017) · Environment International · doi:10.1016/j.envint.2017.11.018 · Cited by 61
Hanazawa, T., Asayama, K., Watabe, D., Tanabe, A., Satoh, M., Inoue, R., Hara, A., Obara, T., Kikuya, M., Nomura, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008509 · Cited by 61
Treatment of Hypertension in Chronic Kidney Disease
Kalaitzidis, R., & Elisaf, M. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0864-0 · Cited by 61
Metabolic Surgery for Hypertension in Patients With Obesity
Pareek, M., Bhatt, D. L., Schiavon, C. A., & Schauer, P. R. (2019) · Circulation Research · doi:10.1161/circresaha.118.313320 · Cited by 61
Hypertension in Premenopausal and Postmenopausal Women
Brahmbhatt, Y. G., Gupta, M. M., & Hamrahian, S. M. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0979-y · Cited by 61
Black–White Differences in Cardiovascular Disease Mortality: A Prospective US Study, 2003–2017
Tajeu, G. S., Safford, M. M., Howard, G., Howard, V. J., Chen, L., Long, D. L., Tanner, R. M., & Muntner, P. (2020) · American Journal of Public Health · doi:10.2105/ajph.2019.305543 · Cited by 61
Management der arteriellen Hypertonie
Wermelt, J. A., & Schunkert, H. (2017) · Herz · doi:10.1007/s00059-017-4574-1 · Cited by 61
Older people’s attitudes towards deprescribing cardiometabolic medication
Crutzen, S., Abou, J., Smits, S. E., Baas, G., Hugtenburg, J. G., Heringa, M., Denig, P., & Taxis, K. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02249-z · Cited by 60
Ledwidge, M. T., Dodd, J. D., Ryan, F., Sweeney, C. M., McDonald, K., Fox, R., Shorten, E., Zhou, S., Watson, C. J., Gallagher, J., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0065 · Cited by 62
Myers, M. G., Kaczorowski, J. A., Dolovich, L. R., Tu, K., & Paterson, J. M. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07721 · Cited by 60
Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction
Levy, P. D., Willock, R. J., Burla, M. J., Brody, A., Mahn, J. J., Marinica, A. L., Nasser, S. A., & Flack, J. M. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.10.005 · Cited by 60
Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective
Ferguson, T. W., Tangri, N., Tan, Z., James, M. T., Lavallee, B., Chartrand, C. D., McLeod, L., Dart, A. B., Rigatto, C., & Komenda, P. V. J. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.022 · Cited by 60
Blood Pressure and Arterial Load After Transcatheter Aortic Valve Replacement for Aortic Stenosis
Lindman, B. R., Otto, C. M., Douglas, P. S., Hahn, R. T., Elmariah, S., Weissman, N. J., Stewart, W. J., Ayele, G. M., Zhang, F., Zajarías, A., et al. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.006308 · Cited by 60
Aalen, O. O., Stensrud, M. J., Didelez, V., Daniel, R., Røysland, K., & Strohmaier, S. (2019) · Biometrical Journal · doi:10.1002/bimj.201800263 · Cited by 60
Lopez, P. D., Cativo, E. H., Atlas, S. A., & Rosendorff, C. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.044 · Cited by 60
Bae, E. H., Lim, S. Y., Han, K., Oh, T. R., Choi, H. S., Kim, C. S., Kwon, S., & Kim, S. W. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13422 · Cited by 60
Scaling up effective treatment of hypertension—A pathfinder for universal health coverage
Frieden, T. R., Varghese, C. V., Kishore, S. P., Campbell, N. R. C., Moran, A. E., Padwal, R. S., & Jaffe, M. G. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13655 · Cited by 60
Management of metabolic syndrome and cardiovascular risk after liver transplantation
Fatourou, E. M., & Tsochatzis, E. A. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30181-5 · Cited by 59
Chiang, C., Wang, T., Lin, T., Yeh, H., Liu, P., Cheng, H., Chao, T., Chen, C., Shyu, K., Ueng, K.-C., et al. (2017) · Europe PMC (PubMed Central) · doi:10.6515/acs20170421a · Cited by 59
Blood pressure targets in adults with hypertension
Arguedas, J. A., Leiva, V., & Wright, J. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004349.pub3 · Cited by 59
Theory vs Practice: Should Primary Care Practice Take on Social Determinants of Health Now? No.
Solberg, L. I. (2016) · The Annals of Family Medicine · doi:10.1370/afm.1918 · Cited by 59
Nishizawa, M., Hoshide, S., Okawara, Y., Matsuo, T., & Kario, K. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12864 · Cited by 59
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 59
Burgess, L. G., Goyal, N., Jones, G. M., Khorchid, Y. M., Kerro, A., Chapple, K. M., Tsivgoulis, G. K., Alexandrov, A. V., & Chang, J. J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008439 · Cited by 59
Stern, M. E., Broja, M., Sansone, R., Gröne, M., Skene, S. S., Liebmann, J., Suschek, C. V., Born, M., Kelm, M., & Heiß, C. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318800072 · Cited by 59
Sharrief, A. Z., & Grotta, J. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00021-2 · Cited by 59
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
